The Association BetweenNQO1Pro187Ser Polymorphism and Urinary System Cancer Susceptibility: A Meta-Analysis of 22 Studies

Zhang, Yan; Yang, Dong; Zhu, Jinhong; Chen, Min-Bin; Shen, Wenxiang; He, Jing

doi:10.3109/07357907.2014.998836

Cited by 12 publications

(9 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 36 Some genetic alterations located in the MDM2 gene, such as SN309, 37 have been proved to be associated with cancer risk. 16 , 38 , 39 As far as we know, there are at least 4,765 polymorphisms found in the MDM2 gene ( http://www.ncbi.nlm.nih.gov/projects/SNP ). One of the frequently investigated polymorphisms is MDM2 del1518, a common 40 bp Ins/Del polymorphism, located in constitutive promoter with a putative TATA motif.…”

Section: Discussionmentioning

confidence: 99%

MDM2 promoter del1518 polymorphism and cancer risk: evidence from 22,931 subjects

Hua

Zhang

Duan

et al. 2017

OTT

Self Cite

View full text Add to dashboard Cite

Studies have shown that single-nucleotide polymorphisms in MDM2 gene may play important roles in the development of malignant tumor. The association of del1518 polymorphism (rs3730485) in the MDM2 promoter with cancer susceptibility has been extensively studied; however, the results are contradictory. To quantify the association between this polymorphism and overall cancer risk, we conducted a meta-analysis with 12,905 cases and 10,026 controls from 16 eligible studies retrieved from PubMed, Embase, and Chinese Biomedical (CBM) databases. We assessed the strength of the connection using odds ratios (ORs) and 95% confidence intervals (CIs). In summary, no significant associations were discovered between the del1518 polymorphism and overall cancer risk (Del/Del vs Ins/Ins: OR =1.01, 95% CI =0.90–1.14; Ins/Del vs Ins/Ins: OR =1.03, 95% CI =0.96–1.12; recessive model: OR =0.98, 95% CI =0.90–1.07; dominant model: OR =1.03, 95% CI =0.94–1.12; and Del vs Ins: OR =1.01, 95% CI =0.94–1.07). In the stratified analysis by source of control, quality score, cancer type, and ethnicity, no significant associations were found. Despite some limitations, the current meta-analysis provides solid statistical evidence of lacking association between the MDM2 del1518 polymorphism and cancer risk.

show abstract

Section: Discussionmentioning

confidence: 99%

MDM2 promoter del1518 polymorphism and cancer risk: evidence from 22,931 subjects

Hua

Zhang

Duan

et al. 2017

OTT

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, great numbers of association studies have been conducted to explore the relationship between NQO1 Pro187Ser or SULT1A1 Arg213His polymorphism and the risk of BC. Moreover, the increased effects of NQO1 Pro187Ser or SULT1A1 Arg213His polymorphism on the risk of various cancers including BC have been clarified by the previous meta-analyses [14][15][16][17][18][19][20]. Importantly, a certain amount of the original study has not only investigated the individual effect of NQO1 Pro187Ser or SULT1A1 Arg213His on the risk of BC but has also examined the genetic effect of NQO1 Pro187Ser or SULT1A1 Arg213His modified by smoking on BC risk.…”

Section: Introductionmentioning

confidence: 99%

Combined effects of NQO1 Pro187Ser or SULT1A1 Arg213His polymorphism and smoking on bladder cancer risk: Two meta-analyses

Wang

Tao

et al. 2017

Int J Occup Med Environ Health

View full text Add to dashboard Cite

show abstract

“…The concentration of NAD in whole blood was decreased in patients with bladder cancer compared to control subjects, and plasma levels of nicotinamide metabolites were also altered [28]. NQO1, one of the major quinone reductases highly inducible under cellular stress, modulate NAD/NADH redox balance, and specific polymorphism of NQO1 is associated with cancer risk in urinary system [29]. However, the role of NMNAT2 in bladder cancer cells and whether expression of NMNAT2 affects therapeutic efficacy remains unclear.…”

Section: Discussionmentioning

confidence: 99%

Effects of Epigallocatechin Gallate (EGCG) on Urinary Bladder Urothelial Carcinoma―Next-Generation Sequencing and Bioinformatics Approaches

et al. 2019

View full text Add to dashboard Cite

Background and objectives: Bladder urothelial carcinoma is the most common type of genitourinary cancer. Patients with bladder cancer may have limited treatment efficacy related to drug toxicity, resistance or adverse effects, and novel therapeutic strategies to enhance treatment efficacy or increase sensitivity to drugs are of high clinical importance. Epigallocatechin gallate (EGCG) is a polyphenolic compound found in green tea leaves, and a potential anti-cancer agent in various cancer types through modulating and regulating multiple signaling pathways. The current study aimed to explore the role and novel therapeutic targets of EGCG on bladder urothelial carcinoma. Materials and Methods: The BFTC-905 cells, human urinary bladder transitional cell carcinoma (TCC) cell line, were treated with EGCG or water for 24 hours, and the expression profiles of mRNAs and microRNAs were analyzed using next generation sequencing (NGS). The enriched biological functions were determined using different bioinformatics databases. Results: A total of 108 differentially expressed genes in EGCG-treated bladder TCC cells were identified, which were mainly involved in nicotinamide adenine dinucleotide (NAD) biogenesis, inflammatory response and oxidation-reduction metabolism. Moreover, several microRNA-mRNA interactions that potentially participated in the response of bladder TCC to EGCG treatment, including miR-185-3p-ARRB1 (arrestin beta 1), miR-3116-MGAT5B (alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase B), miR-31-5p-TNS1 (tensin 1), miR-642a-5p-TNS1, miR-1226-3p-DLG2 (discs large homolog 2), miR-484-DLG2, and miR-22-3p-PPM1K (protein phosphatase 1K). Conclusions: The current findings provide insights into novel therapeutic targets and underlying mechanisms of action of EGCG treatment in bladder cancer.

show abstract

The Association BetweenNQO1Pro187Ser Polymorphism and Urinary System Cancer Susceptibility: A Meta-Analysis of 22 Studies

Cited by 12 publications

References 43 publications

<em>MDM2</em> promoter del1518 polymorphism and cancer risk: evidence from 22,931 subjects

<em>MDM2</em> promoter del1518 polymorphism and cancer risk: evidence from 22,931 subjects

Combined effects of NQO1 Pro187Ser or SULT1A1 Arg213His polymorphism and smoking on bladder cancer risk: Two meta-analyses

Effects of Epigallocatechin Gallate (EGCG) on Urinary Bladder Urothelial Carcinoma―Next-Generation Sequencing and Bioinformatics Approaches

Contact Info

Product

Resources

About